DUBAI – Moderna and Tabuk Pharmaceutical Manufacturing Company, a fully owned subsidiary of Astra Industrial Group, a leading Saudi pharmaceuticals company, have announced a three-year partnership to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.
Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia. The contract, which is renewable, allows Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future.
Mohammed Alhagbani, President of Astra Industrial Group, said their partnership with Moderna was paramount to achieving their mission to deliver unique health solutions and preserve the lives of the Saudi nationals.
Not so long ago, the US drug maker requested that the FDA approve the coronavirus shot for adolescents age 12 to 17.
Some Moderna recipients have reported heart problems, but the company said that scientific evidence it has reviewed doesn’t suggest that its Covid-19 vaccine was the cause of a heart condition.
The drug maker said in a statement that, after reviewing the available safety data on its shot for cases of myocarditis and pericarditis, it has not established a causal association with its vaccine.
So far, the United Arab Emirates has recorded over 598 thousand cases and 1,726 deaths. The region has managed to fully immunize 39.35% of its population against coronavirus. The country has been heavily reliant on the Sinopharm vaccine for inoculation.
This partnership is set to boost supply and variety of COVID-19 vaccines available in Saudi Arabia and the UAE to bolster efforts of immunizing all those in risk groups as well as the general population.